In the meta-analysis of edema volume observed in breast cancer survivors, two studies indicated some improvement with ProLBS plus FOS intervention (MD = −80.00; 95% CI: −186.01 to 26.01; p = 0.14) but did not achieve statistical significance (Figure 9). The gene discussed is FOS; the disease is breast cancer.